Targeted therapies in myelodysplastic syndrome

Seminars in Hematology
Magda Melchert, Alan F List

Abstract

Therapeutic alternatives for patients with myelodysplastic syndrome (MDS) have expanded in recent years but remain limited. While agents approved by the US Food and Drug Administration (FDA), including azacitidine, decitabine, and lenalidomide, have yielded hematologic and cytogenetic responses in a substantial portion of patients, these therapies are not curative. Active investigation of novel targets with biological relevance in myelopoiesis has stimulated the pharmacologic development of a multitude of agents that show promise in the treatment of MDS. Many of these drugs have entered or completed early phase clinical testing in MDS and include immunomodulatory agents, immunosuppressive therapies, survival signal inhibitors, thrombopoiesis-stimulating agents, pharmacologic differentiators, and anti-angiogenic and apoptotic agents. As we continue to collect clinical experience with these agents, the repertoire of available therapeutics for the treatment of MDS will expand and provide a foundation for novel therapeutic combinations.

References

Dec 24, 1997·British Journal of Haematology·J J MolldremA J Barrett
Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
Aug 6, 2002·Annals of Internal Medicine·Jeffrey J MolldremA John Barrett
Feb 18, 2003·British Journal of Haematology·Sally B KillickJudith C W Marsh
Nov 18, 2003·British Journal of Haematology·Deborah A ThomasHagop Kantarjian
Jan 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Wolf-Karsten HofmannH Phillip Koeffler
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Razelle KurzrockHagop M Kantarjian
Apr 2, 2004·Nature Reviews. Cancer·J Blake BartlettAngus G Dalgleish
Dec 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A-M TsimberidouR Kurzrock
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
May 3, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert VeyPierre Fenaux
May 3, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary J SchillerAlan F List
Jul 11, 2006·Cancer·Alvaro Moreno-AspitiaUNKNOWN North Central Cancer Treatment Group
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
Oct 20, 2006·The New England Journal of Medicine·James B BusselJanet L Nichol
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meir WetzlerHeinz Baumann
Feb 10, 2007·Blood·David J Kuter
Mar 1, 2007·Blood·Julian M JenkinsConnie L Erickson-Miller
Mar 17, 2007·Cancer·Hagop KantarjianJoseph Leveque
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elaine M SloandJohn Barrett

❮ Previous
Next ❯

Citations

Dec 3, 2009·Clinical Lymphoma & Myeloma·Erzsebet KovacsGyorgy Pfliegler
Jan 15, 2009·Journal of Internal Medicine·M Jädersten, E Hellström-Lindberg
Feb 6, 2009·American Journal of Hematology·Margaret T Kasner, Selina M Luger
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Sridhar Srinivasan, Charles A Schiffer
Sep 30, 2017·The Cochrane Database of Systematic Reviews·Helga DodilletNicole Skoetz
Jan 27, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Antonio GidaroRoberto Castelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.